



1-26-06

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Jose Luis Castro Pineiro et al.	
Serial No.:	10/511,507	Case No.: T1573P
US Nat'l Filing Date:	October 15, 2004	
Int'l Appl'n No.	PCT/GB03/01758	
Int'l Filing Date:	April 24, 2003	
For:	ALKYNYL-SUBSTITUTED SPIROCYCLIC SULFAMIDES AS INHIBITORS OF GAMMA-SECRETASE	

Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT January 25, 2006  
EXPRESS MAIL NO. 1E161401121345

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Christina Cyffe  
DATE 1-25-06

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference (1) is the publication of commonly owned, pending U.S. application serial no. 10/415,751, and is the national phase of International application publication no. WO 02/36555, which was submitted with the Information Disclosure Statement mailed October 15, 2004.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: January 25, 2006

**STATEMENT BY APPLICANT**

IAN 2.5 2006

(use as many sheets as necessary)

Sheet

1

of

1

## Application Number

10/511,507

**Filing Date**

October 15, 2004

**First Named Inventor**

Jose Luis Castro Pineiro et al.

## Group Art Unit

1645

Examiner Name

### To Be Assigned

Attorney Docket Number

T1573P

[illegible][illegible]

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005